Trump Launches Discount Drug Platform TrumpRx

Former President Donald Trump on Thursday unveiled TrumpRx.gov, a self-pay prescription drug platform designed to offer discounted prices on 43 brand-name medications. The administration said the initiative aims to lower drug costs for Americans who pay for prescriptions without insurance coverage.

Trump targets high drug prices with TrumpRx rollout

TrumpRx does not dispense medications directly. Instead, it provides discount coupons that customers can present at participating pharmacies. In some cases, the platform redirects users to pharmaceutical companies’ own websites, where they can purchase drugs directly. Several specialty medications, including treatments used in in vitro fertilization, are available only through designated specialty pharmacies.

Trump promoted the platform at a White House event, saying it would deliver major savings and improve access to costly treatments. Officials said the program aligns with Trump’s broader push for a “most favored nation” drug pricing policy, which seeks to ensure that Americans do not pay more for medications than patients in other wealthy nations. According to the administration, at least 16 drugmakers have reached agreements to participate in TrumpRx. At launch, discounted medications came from AstraZeneca, Eli Lilly, EMD Serano, Novo Nordisk, and Pfizer. Popular weight-loss drugs Wegovy and Zepbound featured prominently among the listed discounts.

Also Read : India–US Trade Pact Boosts Youth Opportunities

Some price reductions are significant. The migraine drug Zavzpret, for example, now sells for $549 through TrumpRx, compared with its previous list price of $1,189. Despite the announced savings, health policy experts cautioned that the platform may benefit only a narrow group of patients. Because TrumpRx applies exclusively to cash-paying customers, insured individuals may find lower costs through their existing coverage. In addition, purchases made via TrumpRx do not count toward insurance deductibles or out-of-pocket maximums.

Experts also noted that the platform focuses solely on brand-name drugs, which represent a small share of prescriptions in the United States, where generic medicines account for the vast majority of prescriptions filled. Questions remain about the long-term viability of the discounts and the details of the agreements with drugmakers. The administration said it negotiated lower prices in exchange for tariff relief, a claim that has drawn scrutiny. Consumer advocacy group Public Citizen has filed a lawsuit seeking records related to the negotiations.

Also Read : WPL 4: Smriti-Voll blitz powers RCB to second crown